Fragile X syndrome (FXS) is the leading genetic cause of autism spectrum disorder (ASD) and inherited intellectual disability (ID) worldwide. Preclinical successes in understanding the biology of FXS have led to numerous translational attempts in human clinical trials of therapeutics that target the excitatory/inhibitory neural signaling imbalances thought to underlie FXS. Despite the preclinical success story, the negative results of the human clinical trials have been deemed to be at least in part disappointing by the field. In this commentary, we contend that such negative studies results in clinical trials may actually propel the FXS field forward by serving as important lessons for designing and implementing improved future clinical trials such that can objectively assess the full range of responses to new therapeutics.
, and 842 of the identified targets to date converge on the same cellular pathways as idiopathic ASD [2, 3] . Since FMRP acts as a translational 'brake, ' its absence in FXS causes up-regulation of metabotropic glutamate receptor 5 (mGluR5) [4] and down-regulation of GABA signaling [5] , leading to an excitatory/inhibitory imbalance.
Correcting these imbalances with mGluR5
antagonists or GABA receptor agonists rescues the pathological hallmarks of synaptic function and social behavior in the mouse model of FXS (the FMR1 knock-out) [6, 7, 8] . These preclinical breakthroughs have generated Reflecting the key preclinical findings, the vast majority of the clinical trial studies targeted the aforementioned excitatory/inhibitory imbalances (14/22, 64%) [9] .
Since FXS is a genetic diagnosis and ASD is purely behaviorally defined, FXS is the most- 
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